Exciton Technologies Inc.

June, 2010
  • The Wound Ostomy Continence Nurses (WOCN) Society Conference, Phoenix, AZ, June 12-16, 2010, Booth Number 461
May, 2010
  • Multiple clinical evaluations underway throughout the United States with positive feedback collected
  • Signed exclusive distribution agreement with Caribbean Surgical, a well-founded wound care distributor, for Puerto Rico and area

    • Silvasan


April, 2010
  • European Society of Clinical Microbiology and Infectious Diseases
    Vienna, Austria, April 10-13, 2010
    Dr. Robert Rennie, Site Chief, Department of Laboratory Medicine and Pathology, at the University of Alberta has been invited to make a poster presentation at the European Society of Clinical Microbiology and Infectious Diseases conference in Vienna, Austria. Dr. Rennie's presentation will focus on Exciton's SILVAsan™ product and its ability to effectively prevent the spread of both MRSA and P. aeruginosa on inanimate surfaces within a hospital setting while not presenting any environmental, worker or patient issues.
  • Symposium on Advanced Wound Care
    Orlando, Florida, April 17-20, 2010
    Booth Number: 341
March, 2010
  • Received ISO13485 Certification on March 23, 2010
  • Diabetic Foot Global Conference
    Los Angeles, California, March 18-20, 2010
    Booth Number: 207
February, 2010
  • Conducting exsalt™ SD7 Wound Dressing evaluations at clinical and hospital sites across the USA.
January, 2010
  • Exciton is pleased to announce the exsalt™ SD7 Wound Dressing is now available within the United States under prescription.
  • First patient enrolled in Canada in the Clinical Trial of exsalt™ SD7 Wound Dressing, compared to Xeroform® Petrolatum Dressing.
December, 2009
  • The University of Miami completed an in vivo evaluation of our silver oxysalts technology, which demonstrated superior efficacy against biofilms in comparison to the market-leading silver technology.
September, 2009
  • Exciton received authorization from Health Canada to proceed with Investigational Testing of the exsalt™ SD7 Wound Dressing.  The clinical trial is expected to enroll 25 patients comparing the safety and efficacy of exsalt™ SD7 Wound Dressing in reducing healing time and improving the quality of healing of a standard partial-thickness donor site wound to Xeroform® Petrolatum Dressing. The trial will take place at the Firefighters' Burn Treatment Unit, University of Alberta Hospital under the supervision of Dr. Edward Tredget, Director of the Plastic Surgery Research Laboratory.
August, 2009
  • Exciton was granted funding from the Ingenuity R&D Associates Program. The program’s strategic intent is to increase research expertise and drive innovation in Alberta.  Funds from this program were used to hire a full-time Research Scientist dedicated to the development of next-generation products to add to the Company’s portfolio.
  • Exciton Technologies Receives FDA Approval to Market exsalt™ SD7 Wound Dressing.
    Download the full news release >>
May, 2009
  • Raised $1.25M from angel investors since the start of 2009.
April, 2009
  • Awarded an Alberta Innovation Voucher for $50,000 from Alberta Advanced Education and Technology. The voucher will be used to advance product developments on SILVAsan™ hard surface disinfectant.
  • Received notice of approval for funding, of up to $100,000 from NRC-IRAP to validate Exciton’s pilot-scale roll coating equipment and conduct analysis of materials.
March, 2009
  • Commissioned pilot-scale roll coater for manufacturing the exsalt™ SD7 Wound Dressing. The pilot-scale coater will be used to prepare samples for conducting clinical evaluations as well as create an initial inventory to launch the product.
January, 2009
December, 2008
  • Filed 510(k) application with the US Food and Drug Administration (FDA) for exsalt™ SD7 Wound Dressing.
  • Signed development agreement with Ostrem Chemical Co. Ltd., for SILVAsan™ hard surface disinfectant. http://www.ostrem.com
  • Awarded Phase 3 funding from the Alberta Heritage Foundation for Medical Research (AHFMR), ForeFront Program, in the amount of $500,000. 
    View Article
August, 2008
  • Patent filed for exSOL™ Antimicrobial Silver Solutions.
June, 2008
  • Closed on $2 million in private financing.
April, 2008
  • Received freedom to operate for exSALT™ silver coating technology use.
  • Featured in TEC Edmonton Annual Report.
  • Feature article in “Cool Companies” magazine
    (vol 4 issue 1 2008-2009).
January, 2008
  • Expanded the company by moving into the new Enterprise Square facility and hired three new staff including VP Business Development and two Chemists.
November 27, 2007
  • The United States Patent Office issued a patent to Exciton for coating materials with exSALT™ silver coating technology.